Abstract
Mexiletine is a new antiarrhythmic agent that resembles lidocaine in its structure and activity. However, mexiletine is superior to lidocaine in that it is absorbed from the gastrointestinal tract, does not undergo significant first-pass hepatic elimination, and has a relatively long plasma elimination half-life. These properties make mexiletine, unlike lidocaine, suitable for oral administration. Numerous studies have confirmed that mexiletine effectively suppresses ventricular arrhythmias at all ages.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Weld FM, et al: Effects of mexiletine (Kö 1173) on electrophysiological properties of sheep cardiac Purkinje fibers [abstr]. Am J Cardiol 39:292, 1977.
Haap K, Antoni H: Mexiletine—tierexperimentelle Befunde über die antiarrhythmichen und electrophysiologischen Effeckte am Herzen. Klin Wochenschr 56:169, 1978.
Hohnloser S, et al: Effects of mexiletine on steady-state characteristics and recovery kinetics of V|1max and conduction velocity in guinea pig myocardium. J Cardiovasc Pharmacol 4:232, 1982.
Vaughan Williams EM: Mexiletine in isolated tissue models. Postgrad Med J [Suppl 1] 53:30, 1977.
Campbell NPS, et al: Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet 2:404, 1973.
Achuff SC, et al: Mexiletine in the prevention of ventricular arrhythmias in acute myocardial infarction. Posgrad Med J [Suppl 1] 53:163, 1977.
Talbot RG, et al: Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet 2:399, 1973.
Campbell NPS, et al: Prophylactic and long-term therapy with mexiletine. Postgrad Med J [Suppl 1] 53:143, 1977.
Lang KF, et al: Untersuchungen über die Einwirkung von mexiletine (Kö 1173) auf die AV-Überletiungszeit und die Sinusimpulsautomatie bei Herzgesunden und Patienten mit Erkrankung des Reizleitungssystems. Z Kardiol 64:389, 1975.
Seipel L, Breithardt: Electrophysiological effects of mexiletine in man: influence on stimulus-induced ventricular arrhythmias. In: Sandøe E, et al (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam, 1978, p 219.
Probst P, Joskowics G: Die Wirkung von mexiletine auf die AV-Überleitung. Herz-Kreisl 8:81, 1976.
Roos JC, Dunning AJ: Electrophysiological effects of mexiletine, a new antiarrhythmic drug, in man [abstr]. Circulation [Suppl 2] 52:11-233, 1975.
Roos JC, et al: Electrophysiological effects of mexiletine in man. Br Heart J 38:1262, 1976.
Aselbarth Y, et al: Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 29:729, 1981.
Jewitt D: Clinical electrophysiological effects of mexiletine. In: Sandøe E, et al (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam, 1978, p 237.
Iwamura N, et al: Electrophysiological actions of a new antiarrhythmic agent on isolated preparations of the canine Purkinje fiber and ventricular muscle. Cardiology (Basel) 61:329, 1976.
Waspe LE, et al: Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients. Am J Cardiol 51:1175, 1983.
Singh JB, et al: Efficacy of mexiletine in chronic ventricular arrhythmias compared with quinidine: a single-blind, randomized trial. Am J Cardiol 53:84, 1984.
Haselbarth V, et al: Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 29:729, 1981.
Prescott LF, et al: Absorption, distribution and elimination of mexiletine. Postgrad Med J [Suppl 1] 53:50, 1977.
Campbell RWF, et al: Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. Lancet 1:1257, 1975.
Merx W, et al: Mexiletine in acute myocardial infarction. In: Sandøe E, et al (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam, 1978, p 472.
Campbell NPS, et al: The clinical pharmacology of mexiletine. Br J Clin Pharmacol 6:103, 1978.
Graeme Sloman J, et al: Tolerance and side effects of oral mexiletine. In: Sandøe E, et al (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam, 1978, p 329.
Podrid PJ, Lown B: Mexiletine for ventricular arrhythmias. Am J Cardiol 47:895, 1981.
Bell JW: The central nervous system side effects of antiarrhythmic agents. In: Sandøe E, et al (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam, 1978, p 334.
Bernard R, et al: Mexiletine in acute myocardial infarction: tolerance and haemodynamic effects. In: Sandøe E, et al (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam, 1978, p 324.
Velebit V, et al: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65:886, 1982.
Elharrar V, et al: Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol 39:544, 1979.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Schneeweiss, A., Schettler, G. (1988). Mexiletine. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_30
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2063-0_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9225-8
Online ISBN: 978-1-4613-2063-0
eBook Packages: Springer Book Archive